Complicated pneumonia in a vaccinated child –⁠ caused by Streptococcus pneumoniae serotype 3

Czech version

Authors: Daniel Točík ¹; Adam Švepeš ¹; Jan Hřídel ¹; Sandra Vohrnová ^2,3; Jana Kozáková ²; Jakub Jonáš ⁴
Authors‘ workplace: Dětské oddělení, Nemocnice České Budějovice a. s. ¹; Národní referenční laboratoř pro streptokokové nákazy, Centrum epidemiologie a mikrobiologie, Státní zdravotní ústav, Praha ²; 3. lékařská fakulta, Univerzita Karlova, Praha ³; Klinika anesteziologie, resuscitace a intenzivní medicíny, 2. lékařská fakulta, Univerzita Karlova a Fakultní nemocnice Motol, Praha ⁴
Published in: Čes-slov Pediat 2025; 80 (6): 286-290.
Category: Case Report
doi: https://doi.org/10.55095/CSPediatrie2025/037

Overview

Streptococcus pneumoniae remains the leading cause of pneumonia in children under 5 years of age worldwide, despite established vaccination programs. This case report describes a severe course of pneumonia complicated with fluidothorax, lung atelectasis and necrosis of lung parenchyma, requiring surgical intervention. The causative pathogen was identified as Streptococcus pneumoniae, specifically serotype 3, which is included in the pneumococcal conjugate vaccine administered to the patient previously according to the recommended schedule. Serotype 3 in one of the most frequently reported pneumococcal serotypes assosiated with vaccine failure.

Keywords:

vaccination – Streptococcus pneumoniae – pneumonia – fluidothorax – serotype 3

Sources

1. WHO. Pneumonia in children. Dostupné na: https://www.who.int/news-room/fact-sheets/detail/pneumonia

2. Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018; 6(7): e744–e757.

3. GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; 17(11): 1133–1161.

4. Doporučení České vakcinologické společnosti ČLS JEP. Dostupné na: https://www.vakcinace.eu/doporuceni-a-stanoviska

5. ÚZIS ČR. Aktuální data o proočkovanosti české populace. Dostupné na: https://www.nzip.cz/data/ceo/analyticke-studie/ceo-vakcinace-prehled/ceo-vakcinace-prehled.pdf

6. Nelson AL, Roche AM, Gould JM, et al. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun 2007; 75(1): 83–90.

7. Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: serotype 3 pneumococcal disease. Front Cell Infect Microbiol 2020; 10 : 613287.

8. Kim JO, Romero-Steiner S, Sørensen UB, et al. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 1999; 67(5): 2327–33.

9. Hyams C, Camberlein E, Cohen JM, et al. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 2010; 78(2): 704–15.

10. Hammerschmidt S, Wolff S, Hocke A, et al. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect Immun 2005; 73(8): 4653–67.

11. Choi EH, Zhang F, Lu YJ, et al. Capsular polysaccharide (CPS) release by serotype 3 pneumococcal strains reduces the protective effect of anti-type 3 CPS antibodies. Clin Vaccine Immunol 2015; 23(2): 162–7.

12. Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014; 14(9): 839–46.

13. Invazivní pneumokoková onemocnění v České republice. Zprávy Centra epidemiologie a mikrobiologie. Dostupné na: https: //szu.gov.cz/temata-zdravi-a-bezpecnosti/a-z-infekce/s/streptokokova-infekce/invazivni-pneumokokova-onemocneni-v-ceske-republice/

14. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15(3): 301–9.

15. Savulescu C, Krizova P, Lepoutre A, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in

SpIDnet countries: an observational multicentre study. Lancet Respir Med 2017; 5(8): 648–656.

16. Slotved HC, Dalby T, Harboe ZB, et al. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon 2016; 2(11): e00198.

17. Wijayasri S, Hillier K, Lim GH, et al. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017. PLoS One 2019; 14(12): e0226353.

18. Ho PL, Law PY, Chiu SS. Increase in incidence of invasive pneumococcal disease caused by serotype 3 in children eight years after the introduction of the pneumococcal conjugate vaccine in Hong Kong. Hum Vaccin Immunother 2019; 15(2): 455–458.

19. Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018; 18(4): 441–451.

20. Goettler D, Streng A, Kemmling D, et al. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine 2020; 38(3): 570–577.

21. Mungall BA, Hoet B, Nieto Guevara J, et al. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines 2022; 21(2): 201–214.

22. Ricketson LJ, Bettinger JA, Sadarangani M, et al. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine 2022; 40(19): 2733–2740.

23. Feemster K, Weaver J, Buchwald U, et al. Pneumococcal vaccine breakthrough and failure in infants and children: a narrative review. Vaccines (Basel) 2023; 11(12): 1750.

24. Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57(7): 952–62.

25. Lupinacci R, Rupp R, Wittawatmongkol O, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine 2023; 41(5): 1142–1152.

26. Wagner G, Gartlehner G, Thaler K, et al. Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis. npj Vaccines 2024; 9 : 257.

27. Heinige P, Slováková L, Vočková J, et al. Impact of the COVID-19 pandemic on pediatric pneumonia outcomes: a five-year retrospective cohort study. Infect Drug Resist 2025; 18 : 3511–3525.